MOTS-c

MOTS-c research material, available in 10 mg, 40 mg vials. For in-vitro research only.

• The identifying report located a short open reading frame within the mitochondrial 12S ribosomal RNA gene encoding a 16-amino-acid peptide, and reported that its cellular actions inhibit the folate cycle and the de novo purine biosynthesis tethered to it, leading to AMPK activation. [1]
• Under metabolic stress the peptide translocated from mitochondria to the nucleus in an AMPK-dependent manner and regulated nuclear genes including those carrying antioxidant response elements, interacting with the transcription factor NFE2L2, also called NRF2. [2]
• In differentiated C2C12 myotubes the peptide prevented palmitic-acid-induced atrophy, and the authors traced the effect through CK2, PTEN, mTORC2, AKT and FOXO1 to lower myostatin expression. [3]
• A mutant peptide carrying a single Y8F substitution in the YIFY region failed to reproduce the wild-type effects on myotube formation and on STAT3 transcriptional activity, identifying that region as necessary in these assays. [4]

Compound

MOTS-c

Purity

99.10% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg · 40 mg

Catalog / lot

RV-0032 / RV-24-0032-2

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.